THE UNIVERSITY OF HONG KONG

Precision BioSciences received approval in Hong Kong for PBGENE-HBV Phase 1 ELIMINATE-B trial, targeting chronic hepatitis B. The trial aims to eliminate cccDNA and inactivate integrated HBV DNA, potentially leading to functional cures. The study is global and multi-site, with recruitment ongoing, and expected to report data throughout 2025. A U.S. IND is anticipated in 2025.

Scientists reprogrammed mouse cells into pluripotent stem cells using a choanoflagellate gene, creating a chimeric mouse to demonstrate ancient gene compatibility, highlighting evolutionary tools' effectiveness in complex life forms and potential for regenerative medicine breakthroughs.

A groundbreaking AI-powered risk prediction tool, P-CARDIAC, is set to revolutionize CVD prevention and management in the Chinese population, led by Professor Celine Chui Sze-ling at The University of Hong Kong. The HEARTWISE study will evaluate P-CARDIAC's effectiveness in secondary care, focusing on personalized risk assessment, risk thresholds, and pharmacist-led services. The study aims to reduce CVD burden in Hong Kong and beyond, with potential global impact.